AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
A securities class action alleges Aardvark Therapeutics promised investors a "99% gut-restricted" drug with "no serious adverse events" and Phase 3 data in early 2026; instead, cardiac observations paused the HERO trial and the FDA imposed a full clinical hold. NEW YORK, Sept. 2, 2026...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.